Glenmark Guides FY27 Margins at 21-22%; Expects US Sales Over $100 Mn Per Quarter

has guided for operating margins in the range of 21-22% for FY27. The company also stated that its US sales are estimated to exceed $100 million per quarter going forward. The outlook is supported by growth across key markets, including respiratory product launches and strong traction in the US business. Management remains confident of achieving the guided margins despite elevated input and freight costs, while focusing on specialty and branded formulations to drive overall performance. Top stocks in the pharmaceuticals industry: , , and Dr. Reddy’s Laboratories.